Showing results (2051-2060 of 2,138) with videos related to
Sort By:
Pageof 214
Nature Biotechnology|April 24, 2025
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding proteinBenson M George, Maria Eleftheriou, Eliza Yankova, et al.Leukemia|September 11, 2014
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaC Niederwieser, J Kohlschmidt, S Volinia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.Leukemia Research|July 12, 2025
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndromeJames M Foran, Guillermo F Sanz, Justin M Watts, et al.Ophthalmology|February 3, 2024
A Retrospective Longitudinal Study of 460 Patients with ABCA4-Associated Retinal DiseaseBeau J Fenner, S Scott Whitmore, Adam P DeLuca, et al.Biorxiv : the Preprint Server for Biology|September 30, 2024
PTPN11 Mutation Clonal Hierarchy in Acute Myeloid LeukemiaSydney Fobare, Chia Sharpe, Kate Quinn, et al.Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.Blood|June 8, 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.Nature|March 16, 2023
MEN1 mutations mediate clinical resistance to menin inhibitionFlorian Perner, Eytan M Stein, Daniela V Wenge, et al.Pageof 214